In the last trading session, 1.61 million shares of the C4 Therapeutics Inc (NASDAQ:CCCC) were traded, and its beta was 2.94. Most recently the company’s share price was $4.42, and it changed around $0.52 or 13.33% from the last close, which brings the market valuation of the company to $353.60M. CCCC currently trades at a discount to its 52-week high of $11.88, offering almost -168.78% off that amount. The share price’s 52-week low was $1.06, which indicates that the current value has risen by an impressive 76.02% since then. We note from C4 Therapeutics Inc’s average daily trading volume that its 10-day average is 1.49 million shares, with the 3-month average coming to 1.07 million.
C4 Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.89. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 4 recommended CCCC as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. C4 Therapeutics Inc is expected to report earnings per share of -0.37 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
C4 Therapeutics Inc (NASDAQ:CCCC) trade information
Instantly CCCC has showed a green trend with a performance of 13.33% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.63 on recent trading dayincreased the stock’s daily price by 4.54%. The company’s shares are currently down -21.77% year-to-date, but still down -2.86% over the last five days. On the other hand, C4 Therapeutics Inc (NASDAQ:CCCC) is -25.96% down in the 30-day period. We can see from the shorts that 7.4 million shares have been sold at a short interest cover period of 8.36 day(s).
The consensus price target as assigned by Wall Street analysts is $20, which translates to bulls needing to increase their stock price by 77.9% from its current value. Analyst projections state that CCCC is forecast to be at a low of $20 and a high of $20.
C4 Therapeutics Inc (CCCC) estimates and forecasts
C4 Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -5.15 percent over the past six months and at a 46.44% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be 72.28%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 3.6M in revenue for the current quarter. The company’s sales for the same quarters a year ago were 3.26M and 3.04M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 10.40%. Forecasts for the next quarter put sales growth at -100.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -36.05%. C4 Therapeutics Inc earnings are expected to increase by 43.52% in 2024, but the outlook is positive 22.30% per year for the next five years.
CCCC Dividends
C4 Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.44% of C4 Therapeutics Inc shares, and 92.85% of them are in the hands of institutional investors. The stock currently has a share float of 104.84%. C4 Therapeutics Inc stock is held by 163.0 institutions, with LYNX1 CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 9.9993% of the shares, which is about 6.88 million shares worth $31.79 million.
RA CAPITAL MANAGEMENT, L.P., with 7.0891% or 4.88 million shares worth $22.54 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
